Table 1 Demographic and Baseline Characteristics.
From: Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19
Characteristic | Total (N = 52,006) | Remdesivir-exposed (n = 17,164) | Unexposed (n = 34,842) | SMD |
|---|---|---|---|---|
Sex, n (%) | 0.06 | |||
Male | 25,484 (49.0) | 8727 (50.8) | 16,757 (48.1) | |
Female | 26,522 (51.0) | 8437 (49.2) | 18,085 (51.9) | |
Age, years, mean (SD) | 59 (18.3) | 57 (16.4) | 60 (19.1) | 0.13 |
Maximal level of oxygen support on Day 0 or 1, n (%) | 0.23 | |||
Room/ambient air | 33,810 (65.0) | 10,006 (58.3) | 23,804 (68.3) | |
Low-flow oxygen | 10,458 (20.1) | 4189 (24.4) | 6269 (18.0) | |
High-flow oxygen/noninvasive ventilation | 5265 (10.1) | 2209 (12.9) | 3056 (8.8) | |
ECMO/invasive mechanical ventilation | 2473 (4.8) | 760 (4.4) | 1713 (4.9) | |
ICU admission on Day 0 or 1, n (%) | 25,221 (48.5) | 8608 (50.2) | 16,613 (47.7) | 0.05 |
Concomitant medications received on Day 0 or 1, n (%) | ||||
Corticosteroids | 33,849 (65.1) | 16,297 (94.9) | 17,552 (50.4) | 1.16 |
Immunomodulators | 1860 (3.6) | 1390 (8.1) | 470 (1.3) | 0.32 |
Convalescent plasma | 2730 (5.2) | 2070 (12.1) | 660 (1.9) | 0.41 |
Anticoagulants | 13,949 (26.8) | 3161 (18.4) | 10,788 (31.0) | 0.29 |
Immunocompromised* during baseline period,† n (%) | 20,246 (38.9) | 5980 (34.8) | 14,266 (40.9) | 0.13 |
Moderately-to-severely immunocompromised during baseline period,† n (%) | 5673 (10.9) | 1686 (9.8) | 3987 (11.4) | 0.05 |
